It has been recognized for some time that bacterial endotoxins (lipopolysaccharides; LPS) isolated from gram-negative bacteria can elicit a number of profound effects in rabbit platelets both in vitro and in vivo. For example, the injection or infusion of LPS into rabbits will initiate thrombocytopenia accompanied by the appearance of increased systemic levels of both serotonin and platelet factor 3 activity (15, 29, 30 ; G. Evans, A. F. Lewis, and J. F. Mustard, Br. J. Surg. 56:624, 1969) . In many cases, the LPSinitiated thrombocytopenia appears to be biphasic. This response is characterized by an initial rapid sequestration of platelets, a return to the circulation, and a second, more gradual phase of platelet disappearance (1, 2, 31, 32) . In in vitro studies, the incubation of LPS with platelet-rich rabbit plasma also results in destruction of platelet-limiting membranes, platelet aggregation, release of granule-localized serotonin, and generation of platelet factor 3 activity (4, 6, 8, 9, 15, 25) . Initially demonstrated to be dependent upon a heat-labile plasma component (7) , this LPS-initiated platelet response has now been clearly established as being complement dependent (27) . The available evidence has suggested further that rabbit platelet aggregation following exposure to LPS proceeds by generation of immune adherence sites on parti- cles capable of fixing complement (requiring complement components through C3). In contrast, release of serotonin and generation of platelet factor 3 activity proceeds by the complement-dependent bystander "reactive lysis" mechanism (17) and thus requires, in addition to C3, C6 and terminal complement components (2) .
Because of the capacity of endotoxins to initiate complement activation by both the classical pathway (by an antibody-independent interaction of C1 with the lipid A region of the LPS molecule [3, 18, 24] ) and the alternative pathway (by an interaction of alternative pathway components with the polysaccharide region of the LPS molecule [21] ), either or both of these pathways could be responsible for endotoxin-initiated complement-mediated rabbit platelet lysis. However, analogous complement-dependent lytic responses of rabbit platelets to preformed immune precipitates (28) and zymosan (19) would suggest a primary role for the alternative complement pathway. In this report we provide evidence that the capacity to activate the alternative pathway is a necessary requirement for initiation of platelet lysis by endotoxins and that preparations of endotoxins which selectively activate the classical pathway do not initiate platelet lysis. Our experiments have utilized purified LPS from several strains of bacteria, which contain varying amounts of polysaccharide in relation to lipid A as well as isolated lipid A itself. The results of these experiments demonstrate a critical role for the polysaccharide and, hence, ENDOTOXIN-INITIATED PLATELET LYSIS 745 the alternative pathway in endotoxin-initiated complement-dependent rabbit platelet lysis.
MATERIALS AND METHODS LPS. Escherichia coli O111:B4 was grown in a tris(hydroxymethyl)aminomethane-based minimal medium (22) . E. coli 055:B5 and Salmonella minnesota R595 were grown in Trypticase soy broth (BBL, Cockeysville, Md.). The LPS from E. coli 0111:B4 and 055:B5 were extracted by the phenol-water procedure (33) and purified by gel filtration chromatography as previously described (22) . The LPS from E. coli O111:B4 was separated by this procedure into two fractions, both of which have been extensively characterized. The higher-molecular-weight fraction (LPS I) contains, on the average, 8 to 10 repeating oligosaccharide units per lipid A. The lower-molecular-weight * fraction (LPSII), in contrast, contains, on the average, only two to three repeating oligosaccharide units per lipid A. Thus, the relative ratio of lipid A to polysaccharide of the LPS I preparation is about 1:10, and that of the LPS II is about 1:1. These two LPS preparations contain antigenically identical polysaccharides (22) . The LPS from S. Minnesota R595 was extracted by the phenol-chloroform-petroleum ether procedure described by Galanos et al. (10) . This LPS consists only of lipid A and a trisaccharide of 2-keto-3-deoxyoctulosonate. Lipid A was prepared from purified E. coli 055:B5 LPS by mild acid hydrolysis and solubilized with triethylamine as previously described (23) . (At the concentration used in the present experiments [<0.05%], triethylamine had no effect on rabbit platelets, nor did it alter the platelet responses to the LPS preparations.) All LPS preparations were prepared as stock solutions of 10 mg/ml, were maintained at -20oC, and were free of detectable nucleic acid and protein.
Modification of LPS. The E. coli 0111:B4 LPS was treated with sodium hydroxide, using a modification of the procedure described by Neter et al. (26) . LPS, at a concentration of 10 mg/ml, was incubated for 16 h at room temperature with 0.5 N NaOH. After neutralization with HCl, samples were dialyzed extensively against distilled water. Polymyxin B (Sigma Chemical Co., St. Louis, Mo.)-LPS complexes were prepared as previously described (20) , using equal weights of polymyxin B and LPS.
Antisera. Rabbit anti-0111:B4 LPS antibody was prepared essentially as previously described (22) . High-titer rabbit anti-R595 LPS antibody, prepared by the procedure described by Johns et al. (16) (12) and are expressed as a percentage of the total releasable counts (after lysis in Triton X-100). It has earlier been demonstrated that the release of exogenously supplied [3H]serotonin parallels the release of endogenous serotonin and thus provides a convenient measure of the release of densegranule constituents (14) . Backgrounds, which normally were 4 to 8% of the total, were usually subtracted from the experimental results. The data are presented as the average of duplicate samples, which routinely varied by less than 5%. In general, the responses of various preparations of rabbit platelets to LPS in the presence of different sources of plasma did not vary by more than 20%. The relative response of platelets to various preparations of LPS from the same organism was somewhat more variable. The data presented are representative of at least two preparations of platelets and plasma. Preparation of plasma. Rabbits were bled from the central ear artery into 1/10 volume of 3.8% citrate or into heparin (final concentration, 10 U/ml; Riker Laboratories, Northridge, Calif.). Blood was centrifuged at 1,800 x g for 30 min, and the platelet-free plasma was frozen in aliquots at -70'C until used. To obtain rabbit plasma free of C3 and terminal components, rabbits were injected intraperitoneally with the anticomplementary protein from cobra venom (CoF, kindly supplied by Richard Ulevitch, Scripps Clinic and Research Foundation) 24 h prior to bleeding (32) . Plasma so obtained contained less than 5% of normal circulating C3 levels as estimated by immunodiffusion assays and less than 1% of normal hemolytic activity.
RESULTS
Initiation of platelet lysis by LPS. We first examined the capacity of a number of LPS preparations, which have previously been demonstrated to differ significantly in their ability to activate serum complement (21) tivities of these LPS preparations, as estimated by their capacity to reduce the hemolytic titer of human serum, are shown in Table 1 ). The results of this experiment, shown in Fig. 1 Effect of anticoagulants on platelet lysis. Since both the R595 LPS and the isolated lipid A activate only the classical pathway, which requires both calcium and magnesium, the possibility existed that there was an insufficient concentration of calcium in the citrated plasma to allow platelet lysis by these LPS preparations. Therefore, we assessed the capacity of E. coli O11l:B4 LPS and S. minnesota R595 LPS to initiate platelet lysis in both citrated plasma and heparinized plasma. The O111:B4 LPS (alternative pathway) initiated platelet lysis in plasma anticoagulated by either procedure (Fig. 3) Fig. 1 , using the high-percentage-polysaccharide LPS I and the lowpercentage-polysaccharide LPS II isolated from E. coli O111:B4.
In the first, a y globulin fraction of high-titer rabbit anti-R595 antibody was added to normal rabbit plasma and examined for its capacity to affect the response of rabbit platelets to O111:B4 LPS I and R595 LPS. The presence of antibody to the R595 LPS had virtually no detectable effect on the positive response elicited with the polysaccharide-containing LPS preparation (Table 3 ). In addition, however, the anti-R595 antibody, at the concentration tested, did not substantially alter the platelet response to the R595 LPS.
As a second approach, we have investigated the potential contribution of anti-polysaccharide antibody present in normal rabbit plasma to the (PB-LPS), alkaline-treated LPS (BH-LPS), or untreated LPS, all from E. coli O1 1:B4, were examined for their capacity to initiate rabbit platelet lysis. The experiment was performed as described in the legend to Fig. 1 , using final LPS concentrations of250 pg/ml. ticoagulant provides a more efficient environment for complement-mediated lysis. A similar difference was noted in an earlier study by Des Prez et al. (9) , who showed significantly increased capacity of LPS to aggregate rabbit platelets in heparinized plasma as compared to citrated plasma, although the magnitude of the difference in this study (>10-fold) was much greater than that realized in the present study ('2-fold). However, it is difficult to make quantitative comparisons between platelet aggregation and lysis. Nevertheless, both studies show increased effects of LPS in heparinized versus citrated plasma. This may in part reflect the effect of citrate on binding divalent cations required for efficient complement activation.
The results of our in vitro studies failing to demonstrate detectable complement-dependent rabbit platelet lysis by R595 LPS may be contrasted with earlier studies on the in vivo effects of this LPS preparation on circulating platelets. As shown by Ulevitch et al. (32) , the intravenous administration of 50 jg of R595 LPS into rabbits initiated a biphasic change in 5"Cr-labeled platelets. Of particular interest is that the initial rapid decrease was shown to be dependent upon complement components through C3, since this effect was almost completely abrogated in CoFtreated but not C6-deficient rabbits. The results of our in vitro experiments, therefore, might suggest that the rapid complement-dependent in vivo sequestration of platelets following injection of R595 LPS may not occur as a result of a direct LPS-platelet interaction. This might, therefore, provide an explanation for the observation that significantly lower concentrations of LPS are required to achieve in vivo effects than those used in the present in vitro studies. (21) , whereas the former may be a more efficient activator of complement (Table 1) , the latter appears to be more efficient at initiating platelet lysis (Fig. 1) . Thus, some other factor must also contribute to the ability of various LPS preparations to initiate platelet lysis. In this respect, it would be interesting to speculate that the capacity of various preparations of LPS to activate the alternative pathway may reflect the relative affinity of interaction between activated C3 and the polysaccharide portion of the LPS molecule. Such a hypothesis, however, remains yet to be experimentally tested.
These experiments suggest that natural antibody to the LPS does not contribute significantly to the LPS-initiated lysis. The addition of relatively high-titer rabbit anti-R595 LPS antibody neither induced lysis or secretion with R595 LPS nor altered the response to a polysaccharide-containing LPS. Since anti-lipid A antibody can be clearly distinguished from anti-R595 LPS antibody (16) , these experiments cannot definitely rule out a potential role for natural anti-lipid A antibody. However, as only relatively low titers of antibody to lipid A can be obtained in rabbits, even after extensive hyperimmunization, a major role for such antibody would not be anticipated (16) . Additional experiments in which modification of the LPS has been performed without alteration of the antibody-binding capacity of the molecule have in addition ruled out a major role for natural antipolysaccharide antibody. These experiments do, however, strongly suggest that, although lipid A is itself incapable of initiating platelet lysis, it does play an important role in the mechanism leading to lysis by LPS and complement. Our current experiments are aimed at defining that role.
